Evidence map›Paper›PMID 36580664›Full record

ArticleBlood2023

Type 2B von Willebrand disease mutations differentially perturb autoinhibition of the A1 domain.

Emily R Legan, Yi Liu, Nicholas A Arce, Ernest T Parker, Pete Lollar, X Frank Zhang, Renhao Li

Open access · bronzeAbstract read
In one paragraph

Article in Blood, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Structure-resolved dynamics of type 2M von Willebrand disease.Journal of thrombosis and haemostasis : JTH · 2025
    Article
  4. Application of genetic testing for the diagnosis of von Willebrand disease.Journal of thrombosis and haemostasis : JTH · 2024
    Review
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Emily R LeganAflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Department of Pediatrics, Emory University School of Medicine, Emory University, Atlanta, GA.
Yi LiuDepartment of Bioengineering, Lehigh University, Bethlehem, PA.ORCID 0000-0001-5937-358X
Nicholas A ArceAflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Department of Pediatrics, Emory University School of Medicine, Emory University, Atlanta, GA.ORCID 0000-0002-0019-0380
Ernest T ParkerAflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Department of Pediatrics, Emory University School of Medicine, Emory University, Atlanta, GA.
Pete LollarAflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Department of Pediatrics, Emory University School of Medicine, Emory University, Atlanta, GA.ORCID 0000-0002-1206-8104
X Frank ZhangDepartment of Biomedical Engineering, University of Massachusetts Amherst, Amherst, MA.ORCID 0000-0002-8778-595X
Renhao LiAflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Department of Pediatrics, Emory University School of Medicine, Emory University, Atlanta, GA.ORCID 0000-0002-5806-5080
Emory University · USLehigh University · USUniversity of Massachusetts Amherst · US

Funding

Structure and Function of Platelet Glycoprotein lb-IX-V ComplexR01HL082808 · NHLBI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI LI, RENHAO · 2006 to 2023
$6.4M
Conformational activation of von Willebrand factorR01HL143794 · NHLBI · EMORY UNIVERSITY · PI LI, RENHAO · 2018 to 2021
$2.7M
Mechanical regulation of von Willebrand factorR01HL153986 · NHLBI · UNIVERSITY OF MASSACHUSETTS AMHERST · PI ZHANG, XIAOHUI · 2021 to 2024
$2.2M
von Willebrand factor and thrombocytopenia in infective endocarditisF31HL149357 · NHLBI · EMORY UNIVERSITY · PI LEGAN, EMILY ROSE · 2019 to 2022
$147k
Targeting the force-regulated von Willebrand Factor autoinhibitory moduleF31HL154656 · NHLBI · EMORY UNIVERSITY · PI ARCE, NICHOLAS · 2020 to 2021
$80k
NHLBI NIH HHS F31 HL149357NHLBI NIH HHS F31 HL154656NHLBI NIH HHS R01 HL082808NHLBI NIH HHS R01 HL143794NHLBI NIH HHS R01 HL153986
6 · The paper itself

Abstract

Type 2B von Willebrand disease (VWD) is an inherited bleeding disorder in which a subset of point mutations in the von Willebrand factor (VWF) A1 domain and recently identified autoinhibitory module (AIM) cause spontaneous binding to glycoprotein Ibα (GPIbα) on the platelet surface. All reported type 2B VWD mutations share this enhanced binding; however, type 2B VWD manifests as variable bleeding complications and platelet levels in patients, depending on the underlying mutation. Understanding how these mutations localizing to a similar region can result in such disparate patient outcomes is essential for detailing our understanding of VWF regulatory and activation mechanisms. In this study, we produced recombinant glycosylated AIM-A1 fragments bearing type 2B VWD mutations and examined how each mutation affects the A1 domain's thermodynamic stability, conformational dynamics, and biomechanical regulation of the AIM. We found that the A1 domain with mutations associated with severe bleeding occupy a higher affinity state correlating with enhanced flexibility in the secondary GPIbα-binding sites. Conversely, mutation P1266L, associated with normal platelet levels, has similar proportions of high-affinity molecules to wild-type (WT) but shares regions of solvent accessibility with both WT and other type 2B VWD mutations. V1316M exhibited exceptional instability and solvent exposure compared with all variants. Lastly, examination of the mechanical stability of each variant revealed variable AIM unfolding. Together, these studies illustrate that the heterogeneity among type 2B VWD mutations is evident in AIM-A1 fragments.

Indexed as

von Willebrand Disease, Type 2von Willebrand FactorBinding SitesBlood PlateletsHumansMutationPlatelet Glycoprotein GPIb-IX ComplexPlatelet Glycoprotein GPIb-IX Complexvon Willebrand Factor

Identifiers

PMID36580664
PMCPMC10023833
OpenAlexW4313311905

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.